Andrea Dell'Aquila

Cardiologist, Electrophysiologist

Fondazione Poliambulanza Istituto Ospedaliero
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Year:

2026

Catheter ablation is widely performed for the treatment of supraventricular and ventricular arrhythmias; however, specific recommendations regarding antibiotic prophylaxis for femoral-access procedures are lacking in current international guidelines, resulting in substantial practice variability. Although infectious complications are rare, severe events such as infective endocarditis and septic complications have been reported and are associated with significant morbidity and mortality. At the same time, increasing concerns regarding antimicrobial resistance challenge the indiscriminate use of prophylactic antibiotics in low-risk settings, underscoring the need for a more selective and rational approach. This narrative review summarizes the available evidence on infectious complications related to femoral-access catheter ablation and electrophysiological studies. In the absence of prospective data, indirect evidence and biological plausibility were integrated to inform clinical decision-making. Based on multidisciplinary collaboration, we propose a pragmatic, risk-based institutional protocol that discourages routine prophylaxis in low-risk patients while allowing selective antibiotic use in predefined high-risk scenarios. This framework aims to balance patient safety with antimicrobial stewardship and may help reduce unwarranted variability in contemporary electrophysiology practice.

Year:

2026

Year:

2025

Year:

2025

Year:

2025

L’evidenza di fibrillazione atriale subclinica ad un controllo strumentale dei dispositivi intracardiaci è un’entità sempre più frequente, che pone al cardiologo clinico l’interrogativo se iniziare o meno l’anticoagulazione al fine di prevenire gli eventi tromboembolici. Due nuovi trial clinici randomizzati, ARTESIA e NOAH-AFNET6, ci hanno fornito recentemente nuovi dati contrastanti in merito a questo argomento. Da qui una proposta di gestione clinica del paziente che sia semplice ed evidence-based, in attesa di dati più certi.

Year:

2025

Background Performing a left atrial appendage occlusion (LAAO) or catheter ablation with left‐sided intracardiac thrombus is considered very‐high risk for periinterventional stroke. Cerebral embolic protection (CEP) devices are designed to prevent cardioembolic stroke and have been widely studied in TAVR procedures. However, their role in LAAO and catheter ablation of ventricular tachycardia (VT) or in pulmonary vein isolation (PVI) with cardiac thrombus present remains unknown. Purpose to study utility and safety of CEP devices during LAAO and catheter ablation in patients with left sided intracardiac thrombus in a multicenter setting. Methods Two different CEP devices were used according to the physician's discretion: (1) a capture device consisting of two filters for the brachiocephalic and left common carotid arteries placed from a radial artery; or (2) a deflection device covering all three supra‐aortic vessels placed over a femoral artery. Periprocedural and safety data from 2019 to 2023 were retrospectively obtained from procedural reports and discharge letters for all patients with left‐sided intracardiac thrombus undergoing LAAO, VT ablation, or PVI under protection with a CEP device. Long‐term safety data were obtained by clinical follow‐up in the respective institutions and telephone consultations. Results Sixty‐five patients were enrolled in five centers in Italy. Fifty‐two patients underwent LAA closure, 12 patients underwent VT ablation and one patient underwent PVI. Mean age was 73 ± 10 years and 43 (66%) were male, mean LVEF was 46 ± 13%. The location of the cardiac thrombus was the LAA in all 52 patients (100%) undergoing LAA closure whereas in patients undergoing VT ablation, thrombus was present in the LAA in five cases (42%), left ventricle ( n = 6; 50%) and aortic arch ( n = 1;8%). One patient developed left atrial thrombus during PVI. The capture device was used in 39 out of 65 (60%) and the deflection device in 26 out of 65 cases (40%). There were no periprocedural strokes or transitory ischemic attacks (TIA). CEP‐related complications at the arterial access site were noted in 4 cases (6%) and were minor, not requiring surgery. Other periprocedural events were one transient ST‐elevation caused by coronary spasm in a patient undergoing LAA closure, not related to the CEP device. There was one in‐hospital death after VT ablation due to cardiogenic shock, not related to the CEP device. At long‐term follow‐up, one TIA and three non‐cardiovascular deaths occurred with a mean follow‐up time of 455 days. Conclusions This is the first multicentre experience showing that LAA closure or catheter ablation with cerebral protection in patients with cardiac thrombus is feasible without thromboembolic complications. The possibility of safely performing an intervention in this high‐risk setting is promising and should be tested in a prospective randomized trial.

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (6)

Antonio Curcio

Chief

University of Calabria

ITALY
View details

Matthaios Papadimitriou-Olivgeris

Privat-Docent

Lausanne University Hospital

SWITZERLAND
View details

Giuseppe Boriani

University of Modena and Reggio Emilia

ITALY
View details

Claudio Tondo

University of Milan

ITALY
View details

Renato Pascale

Dirigente Medico

IRCCS Azienda Ospedaliero-Universitaria di Bologna

ITALY
View details

Marco Schiavone

Clinical Scientist

Centro Cardiologico Monzino

ITALY
View details